Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02975271 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Phase 2 study, sponsored by Vyne Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02975271: Clinical Trial Phase 2 study, sponsored by Vyne Therapeutics.
NCT02975271 is a Phase 2 study that was terminated before completion, run by Vyne Therapeutics. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02975271, a Phase 2 study, was terminated before completion, sponsored by Vyne Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Study of the Efficacy, Safety \& Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
Interventions
- DRUG Placebo
- DRUG Serlopitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-01-17 |
| Phase | Phase 2 |
Why NCT02975271 stopped before completion
NCT02975271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02975271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02975271 about?
NCT02975271 is a clinical study titled "Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury". Study of the Efficacy, Safety \& Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
What is the current status of trial NCT02975271?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-11. Estimated completion is 2017-01-17.
What interventions are being tested in trial NCT02975271?
The interventions under investigation include: Placebo (DRUG), Serlopitant (DRUG).
Who is sponsoring clinical trial NCT02975271?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02975271's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia